Results per Page:
Viruses are linked to lung disease in hematopoietic cell transplant recipients
From the Boeckh Lab, Vaccine and Infectious Disease and Clinical Research Divisions
Brandeis University honors Fred Hutch molecular biologist
Dr. Steven Henikoff receives 55th Lewis S. Rosenstiel Award for Distinguished Work in Basic Medical Research
Dr. Heather Parsons to lead Fred Hutch’s breast cancer initiatives
Medical oncologist awarded endowed chair to study novel markers for cancer in blood serum
A beacon of light in the dark world of rare cancers
From Drs. Ajay Gopal, Christina Poh, Michi Shinohara and colleagues, Clinical Research Division and University of Washington
Two lifetimes’ worth of bone marrow transplant breakthroughs
Bone marrow transplant pioneer Dr. Rainer Storb retires and reflects on six decades of science and mentorship
Virologist and HIV expert Dr. Michael Emerman retires
Emerman considers mentorship his most important duty in science
Kuni Foundation awards $7M to drive adult oncology research forward
Vancouver, Washington-based foundation supports innovative early-stage research on new potential therapies
Secondary cancer risk following transplant-related immune suppression
From Drs. Phuong Vo and Rainer Storb, Clinical Research Division
Current landscape of metastatic triple-negative breast cancer survival rates
From the Hurvitz Lab, Clinical Research Division
Fred Hutch Cancer Center announces 2025 Evergreen Fund awardees
Nine Fred Hutch researchers receive funding totaling $1.175 million for projects with commercial partnership potential
$600,000 in awards against ovarian cancer for Fred Hutch and UW researchers
Research awarded from the Rivkin Center and Andy Hill CARE fund will dramatically improve outcomes for ovarian cancer patients and the clinicians treating them
What doesn’t kill you makes you stronger
From Dr. Richard Zager, Clinical Research Division
Donor factors influence success of fecal microbiota transplant
From the Rashidi Group, Pathogen Associated Malignancies Program of the Cancer Consortium and Clinical Research Division
Novel regimen greatly reduced chronic GVHD in phase 2 study at Fred Hutch
Substituting cyclophosphamide for a standard post-transplant immunosuppressant is a “gamechanger”